13 completed, 1 enrolling by invitation. 14 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 14 | Completed 13, Enrolling by invitation 1 |
Follow Familial Hypercholesterolemia: new trials by email Literature Review of Familial Hypercholesterolemia trials Research Report on Familial Hypercholesterolemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of Obicetrapib & Ezetimibe Fixed Dose Combination on Top of Maximum Tolerated Lipid-Modifying Therapies Combination Therapy, Monotherapy obicetrapib, Monotherapy ezetimibe - Dyslipidemias, Hypercholesterolemia | Phase 3 | Completed | NewAmsterdam Pharma | 407 | 2024-03-01 | 2025-10-08 |
| A Study of Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-013) CORALreef Lipids Enlicitide Decanoate, Placebo - Hypercholesterolemia, Familial Hypercholesterolemia | Phase 3 | Completed | Merck Sharp & Dohme LLC | 2912 | 2023-08-10 | 2026-09-24 |
| A Study of Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) in Adults With Heterozygous Familial Hypercholesterolemia (MK-0616-017/CORALreef HeFH) Enlicitide Decanoate, Placebo - Hypercholesterolemia, Familial Hypercholesterolemia | Phase 3 | Completed | Merck Sharp & Dohme LLC | 303 | 2023-08-08 | 2026-02-24 |
| Evaluate the Effect of Obicetrapib in Patients With HeFH on Top of Maximum Tolerated Lipid-Modifying Therapies. Obicetrapib, Placebo - Dyslipidemias, High Cholesterol | Phase 3 | Completed | NewAmsterdam Pharma | 354 | 2022-07-25 | 2025-06-11 |
| Improved Diagnosis of Familial Hypercholesterolemia Across the Northland (ID-FH) Motivational interview (MI) - Familial Hypercholesterolemia, Cholesterol, Elevated | Phase 3 | Completed | Essentia Health | 257 | 2022-02-15 | 2026-09-04 |
| Randomized Study to Evaluate the Effect of Obicetrapib on Top of Maximum Tolerated Lipid-Modifying Therapies Placebo, Obicetrapib - Dyslipidemias, High Cholesterol | Phase 3 | Completed | NewAmsterdam Pharma | 2530 | 2021-12-15 | 2025-09-19 |
| Long-term Efficacy and Safety of OLE LIB003 in HoFH, HeFH, and High-risk CVD Patients Requiring Further LDL-C Reduction lerodalcibep - Cardiovascular Disease With Mention of Arteriosclerosis, Elevated Cholesterol | Phase 3 | Enrolling by invitation | LIB Therapeutics LLC | 2000 | 2020-12-03 | 2024-10-22 |
| Safety, Tolerability and Efficacy of Evolocumab (AMG 145) in Children With Inherited Elevated Low-density Lipoprotein Cholesterol (Familial Hypercholesterolemia) Evolocumab - Familial Hypercholesterolemia | Phase 3 | Completed | Amgen | 163 | 2016-09-10 | 2024-05-29 |
| A Clinical Trial to Assess the Long Term Safety and Tolerability of MK-0653H in Japanese Participants With Hypercholesterolemia (MK-0653H-833) Ezetimibe, Rosuvastatin - Hypercholesterolemia, Familial Hypercholesterolemia | Phase 3 | Completed | Organon and Co | 135 | 2016-05-18 | 2024-05-16 |
| Effect of Omega-3 Fatty Acid on Endothelial Function Omega-3, placebo - Familial Hypercholesterolemia | Phase 3 | Completed | Nordlandssykehuset HF | 34 | 2013-03-01 | 2019-05-13 |
| Long Term, Follow-on Study of Lomitapide in Patients With Homozygous Familial Hypercholesterolemia lomitapide - Familial Hypercholesterolemia | Phase 3 | Completed | Aegerion Pharmaceuticals, Inc. | 19 | 2009-10-29 | 2018-06-13 |
| Atorvastatin Three Year Pediatric Study atorvastatin - Familial Hypercholesterolemia | Phase 3 | Completed | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | 272 | 2009-03-01 | 2021-02-21 |
| PLUTO: Pediatric Lipid-redUction Trial of rOsuvastatin Rosuvastatin, Placebo - Familial Hypercholesterolemia | Phase 3 | Completed | AstraZeneca | 173 | 2006-07-01 | 2011-08-31 |
| Ezetimibe (SCH 58235) Taken With Either Atorvastatin or Simvastatin in Participants With Familial Hypercholesterolemia (MK-0653-018) Atorvastatin, Simvastatin, Ezetimibe - Familial Hypercholesterolemia | Phase 3 | Completed | Organon and Co | 50 | 2000-05-03 | 2024-05-10 |
Hyperlipoproteinemia Type II (14) · Hypercholesterolemia (10) · Dyslipidemias (3) · Atherosclerosis (2) · Genetic Diseases, Inborn (2) · Homozygous Familial Hypercholesterolemia (2) · Hyperlipoproteinemias (1) · Lipid Metabolism Disorders (1) · Lipid Metabolism, Inborn Errors (1) · Metabolic Diseases (1)
Congenital, Hereditary, and Neonatal Diseases and Abnormalities (14) · Hyperlipidemias (14) · Metabolism, Inborn Errors (14) · Nutritional and Metabolic Diseases (14) · Hyperlipoproteinemias (13) · Lipid Metabolism Disorders (13) · Lipid Metabolism, Inborn Errors (13) · Metabolic Diseases (13) · Genetic Diseases, Inborn (12) · Dyslipidemias (11) · Arterial Occlusive Diseases (2) · Arteriosclerosis (2) · Cardiovascular Diseases (2) · Vascular Diseases (2)
Ezetimibe (3) · Atorvastatin (2) · MK-0616 (2) · Rosuvastatin Calcium (2) · BMS201038 (1) · Cholesterol Ester Transfer Proteins (1) · Combined Modality Therapy (1) · Docosahexaenoic Acids (1) · Esomeprazole (1) · Motivational Interviewing (1) · Olive Oil (1) · Omacor (1) · Simvastatin (1) · evolocumab (1)
NewAmsterdam Pharma (3) · Merck Sharp & Dohme LLC (2) · Organon and Co (2) · Aegerion Pharmaceuticals, Inc. (1) · Amgen (1) · AstraZeneca (1) · Essentia Health (1) · LIB Therapeutics LLC (1) · Nordlandssykehuset HF (1) · Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (1)
United States (11) · Norway (7) · Canada (6) · Spain (6) · Netherlands (5) · South Africa (5) · Czechia (4) · Italy (4) · Poland (4) · Turkey (Türkiye) (4) · Colombia (3) · Hungary (3) · Israel (3) · Australia (2) · Belgium (2)
Marc Ditmarsch (2) · David Kallend, MB BCh (1) · Marc Ditmarsch, MD (1) · Marina Cuchel, MD, PhD (1) · Mark Sumeray, MD (1)
PMID 12034651, PMID 20223367, PMID 27678432, PMID 36520008, PMID 36999528, PMID 38705341, PMID 39531353, PMID 40337982, PMID 40347969, PMID 41109840, PMID 41206969, PMID 41760952, PMID 41879224, PMID 42054033
2008 (1), 2015 (1)